The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase II a trial of three dosage levels of CP-690,550 versus placebo - Kremer, J M; Bloom, B J; Breedveld, F C (Arthritis Rheum, 2009)